Overall, further functional exploitation of this novel D2R–M1R interaction (i.e., identifying the functional fingerprint of this putative new heterodimer in native tissue) may provide beneficial opportunities in PD treatment. This evidence concerns the gene CHRM1 and Parkinson disease.